Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FELICITA
2025-520539-17-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota in Autism Spectrum Disorder (ASD) and gastrointestinal conditions, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Gastrointestinal symptom response rate. Planned start May 2025; status: authorised.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Autism Spectrum Disorder (ASD)gastrointestinal conditions
Beyond the preview
Go deeper on 2025-520539-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520539-17-00.